Published in Hepatitis Weekly, October 30th, 2006
"Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with HBV genotype A, 38 with genotype B, and 449 with genotype C," wrote M. Kobayashi and colleagues, Toranomon General Hospital.
"Patients with genotype A were younger (median age 37 [range 24-49] vs. 47 [24-67] or 44 [18-73], p=.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, p<.001) and HBV DNA in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.